SCHEMBL7123641

SCHEMBL7123641

COc1ccccc1[S+](c1ccc(C)cc1)c1ccccc1OC.O=S(=O)([O-])c1ccccc1C(F)(F)F

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.42
SLC22A12 Q96S37 7/20 0.40
TP53 P04637 1/20 0.36
MAPT P10636 1/20 0.36
KMT2A Q03164 3/20 0.36
GAA P10253 1/20 0.36
IDO1 P14902 1/20 0.36
CYP2C9 P11712 1/20 0.36
SLC22A6 Q4U2R8 1/20 0.36
SLC22A8 Q8TCC7 1/20 0.36
SLC22A11 Q9NSA0 1/20 0.36
AXL P30530 3/20 0.35
MAOB P27338 1/20 0.35
MEN1 O00255 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2D6 P10635 1/20 0.34
TSHR P16473 1/20 0.34
CYP2C19 P33261 1/20 0.34
HSD11B1 P28845 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2898284 0.85 GAA (0.49) SMN1; SMN2SLC22A12MAPTKMT2AGAA
Trifluoromethanesulfonic Acid SCHEMBL6855511 0.84 GPR3 (0.39) SMN1; SMN2MAPTKMT2AGAAIDO1
SCHEMBL6929151 0.84 GAA (0.40) SMN1; SMN2KMT2AGAAMEN1
SCHEMBL3204977 0.83 SLC22A12 (0.42) SLC22A12KMT2AGAACYP2C9SLC22A6
SCHEMBL6850300 0.83 SMN1; SMN2 (0.39) SMN1; SMN2MAPTKMT2AGAACYP2C9
SCHEMBL6855470 0.80 HTR6 (0.42) SMN1; SMN2MAPTKMT2AGAAMEN1
SCHEMBL450233 0.79 GAA (0.53) SMN1; SMN2SLC22A12MAPTKMT2AGAA
SCHEMBL6856457 0.79 GAA (0.35) SMN1; SMN2MAPTKMT2AGAACYP2C9
SCHEMBL6855382 0.78 SMN1; SMN2 (0.32) SMN1; SMN2MAPTTSHR
SCHEMBL6850172 0.77 SMN1; SMN2 (0.32) SMN1; SMN2MAPTTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030194634-A1 Novel anthracene derivative and radiation-sensitive resin composition JSR CORPORATION (JP) 2003-10-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030194634-A1 Novel anthracene derivative and radiation-sensitive resin composition SRSF1, ARL1, ERCC4 SMN1; SMN2 2465/4885SLC22A12 3579/4885TP53 1685/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.